Resource Type

Journal Article 60

Year

2024 1

2023 3

2022 4

2021 5

2020 10

2019 11

2017 1

2016 2

2015 2

2014 1

2013 3

2012 1

2010 2

2009 4

2008 5

2007 3

open ︾

Keywords

cancer immunotherapy 3

immunotherapy 3

ACE2 2

Chimeric antigen receptor 2

FGF21 2

Klotho 2

SARS-CoV-2 2

acute myeloid leukemia 2

chimeric antigen receptor 2

chimeric antigen receptor T cell 2

cytokine release syndrome 2

endocrine 2

epidermal growth factor receptor 2

prognosis 2

2019-nCoV 1

3T3-L1 1

Acute liver failure 1

Antibiotic 1

Artificial intelligence 1

open ︾

Search scope:

排序： Display mode:

FGF23 associated bone diseases

Eryuan Liao

Frontiers of Medicine 2013, Volume 7, Issue 1,   Pages 65-80 doi: 10.1007/s11684-013-0254-6

Abstract:

Recently, fibroblast growth factor 23 (FGF23) has sparked widespread interest because of its potentialIn this review, we summarized the FGF superfamily, the mechanism of FGF23 on phosphate and vitamin Dmetabolism, and the FGF23 related bone disease.

Keywords： fibroblast growth factor 23     FGF receptor     phosphate metabolism     Klotho     bone disease    

HTML PDF Collect

The FGF metabolic axis

Xiaokun Li

Frontiers of Medicine 2019, Volume 13, Issue 5,   Pages 511-530 doi: 10.1007/s11684-019-0711-y

Abstract: Members of the fibroblast growth factor (FGF) family play pleiotropic roles in cellular and metabolicDuring evolution, the ancestor FGF expands into multiple members by acquiring divergent structural elementsBy contrast, FGF19, 21, and 23 coevolve through losing binding affinity for extracellular matrix heparanFGF19 metabolic axis from the ileum to liver negatively controls diurnal bile acid biosynthesis.The significant divergence in structural elements and multiple functional specifications of FGF19, 21

Keywords： FGF19     FGF21     FGF23     FGFR     metabolism     endocrine     Klotho    

HTML PDF Collect

FGF13 suppresses acute myeloid leukemia by regulating bone marrow niches

Frontiers of Medicine 2022, Volume 16, Issue 6,   Pages 896-908 doi: 10.1007/s11684-022-0944-z

Abstract: Fibroblast growth factor 13 (FGF13) is aberrantly expressed in multiple cancer types, suggesting itsResults showed that FGF13 was lowly expressed in patients with AML and that its elevated expression wasUnivariate and multivariate Cox regression analyses identified FGF13 as an independent prognostic factorA prognostic nomogram integrating FGF13 and clinicopathologic variables was constructed to predict 1-The xenograft study indicated that FGF13 overexpression prolonged the survival of recipient mice.

Keywords： acute myeloid leukemia     FGF13     prognosis     immune-related genes     bone marrow niches    

HTML PDF Collect

Influence of retinoic acid on TBX1 expression in myocardial cells induced by Shh and Fgf8

Miao LIU, Xiaoyan WU, Jiawei XU, Runming JIN

Frontiers of Medicine 2009, Volume 3, Issue 1,   Pages 61-66 doi: 10.1007/s11684-009-0007-8

Abstract: The expression of Shh and Fgf8 at mRNA and protein levels in neonatal rat myocardial cells were measuredThere was basal expression of Shh and Fgf8 in the control group.Meanwhile, we could detect that the expression of Fgf8 mRNA and protein were up-regulated by 2.50 timesThe results indicated that RA could induce the expression of Shh and Fgf8 in neonatal rat myocardialAt the same time, it has shown that Shh and Fgf8 were involved in the regulation process of RA on TBX1

Keywords： retinoic acid     Tbx1 protein     Shh protein     Fgf8 protein    

HTML PDF Collect

Nicotinic acetylcholine receptor α7 subunit: a novel therapeutic target for cardiovascular diseases

Chong Liu, Dingfeng Su

Frontiers of Medicine 2012, Volume 6, Issue 1,   Pages 35-40 doi: 10.1007/s11684-012-0171-0

Abstract: cholinergic anti-inflammatory pathway,” more specifically via the α7 nicotinic acetylcholine receptor

Keywords： α7 nicotinic acetylcholine receptor     cardiovascular diseases     baroreflex sensitivity    

HTML PDF Collect

Resistance to receptor tyrosine kinase inhibition in cancer: molecular mechanisms and therapeutic strategies

Peter B. Alexander,Xiao-Fan Wang

Frontiers of Medicine 2015, Volume 9, Issue 2,   Pages 134-138 doi: 10.1007/s11684-015-0396-9

Abstract: In this review, we discuss the main known mechanisms of resistance to receptor tyrosine kinase inhibitorsoutput, and consider the problems of signaling pathway redundancy and how the activation of different receptor

Keywords： targeted therapy     drug resistance     receptor tyrosine kinases     cancer    

HTML PDF Collect

Fibroblast growth factor 21: a novel metabolic regulator from pharmacology to physiology

Huating Li, Jing Zhang, Weiping Jia

Frontiers of Medicine 2013, Volume 7, Issue 1,   Pages 25-30 doi: 10.1007/s11684-013-0244-8

Abstract:

Fibroblast growth factor 21 (FGF21) is a member of the fibroblast growth factor family.It is demonstrated that FGF21 acts on multiple tissue to coordinate carbohydrate and lipid metabolismMoreover, FGF21 also plays important roles in some physiological processes, such as fasting and feedingClinical relevance of FGF21 in humans is still unclear, and the basis and consequences of increased FGF21This article concentrates on recent advances in our understanding of FGF21.

Keywords： FGF21     metabolism     pharmacology     physiology     clinical relevance    

HTML PDF Collect

Overcoming resistance to endocrine therapy in hormone receptor-positive human epidermal growth factorreceptor 2-negative (HR

Wenjie Zhu, Binghe Xu

Frontiers of Medicine 2021, Volume 15, Issue 2,   Pages 208-220 doi: 10.1007/s11684-020-0795-4

Abstract: New targeted therapies have been developed to overcome resistance to endocrine therapy (ET) and improve the outcome of HR /HER2 advanced breast cancer (ABC). We conducted a meta-analysis and systemic review on randomized controlled trials evaluating various targeted therapies in combination with ET in HR /HER2 ABC. PUBMED and EMBASE databases were searched for eligible trials. Hazard ratios (HRs) for progression-free survival (PFS), odds ratios (ORs) for objective response rate (ORR), clinical benefit rate (CBR), and toxicity were meta-analyzed. Twenty-six studies with data on 10 347 patients were included and pooled. The addition of cyclin-dependent kinase 4/6 inhibitors to ET significantly improved median PFS (pooled HR= 0.547, <0.001), overall survival (pooled HR= 0.755, <0.001), and tumor response rates (ORR, pooled OR= 1.478, <0.001; CBR, pooled OR= 1.201, <0.001) with manageable toxicities (pooled OR= 3.280, <0.001). The mammalian targets of rapamycin inhibitors and exemestane were not clinically beneficial for this pooled population including ET-naïve and ET-resistant patients. Moderate improvement in PFS (pooled HR= 0.686, <0.001) yet pronounced toxicities (pooled OR= 2.154, <0.001) were noted in the combination of phosphatidylinositol-4,5-bisphosphate 3-kinase inhibitors with fulvestrant. Future studies are warranted to optimize the population and the dosing sequence of these available options.

Keywords： endocrine-resistant     HR+/HER2- advanced breast cancer     randomized clinical trials     meta-analysis     targeted therapy    

HTML PDF Collect

microenvironment contributes to tumor progression in diffuse large B-cell lymphoma upon anti-CD19 chimeric antigen receptor

Frontiers of Medicine 2023, Volume 17, Issue 4,   Pages 699-713 doi: 10.1007/s11684-022-0972-8

Abstract: Anti-CD19 chimeric antigen receptor (CAR)-T cell therapy has achieved 40%–50

Keywords： anti-CD19 chimeric antigen receptor T     immunotherapy     diffuse large B cell lymphoma     tumor microenvironment    

HTML PDF Collect

Chimeric antigen receptor T cell therapies for acute myeloid leukemia

Bin Gu, Jianhong Chu, Depei Wu

Frontiers of Medicine 2020, Volume 14, Issue 6,   Pages 701-710 doi: 10.1007/s11684-020-0763-z

Abstract: Abstract Chimeric antigen receptor T cell (CAR T) therapies have achieved unprecedented efficacy in B-cell

Keywords： acute myeloid leukemia     CAR T     immunotherapy    

HTML PDF Collect

Chimeric antigen receptor T cell targeting EGFRvIII for metastatic lung cancer therapy

Zhao Zhang, Jun Jiang, Xiaodong Wu, Mengyao Zhang, Dan Luo, Renyu Zhang, Shiyou Li, Youwen He, Huijie Bian, Zhinan Chen

Frontiers of Medicine 2019, Volume 13, Issue 1,   Pages 57-68 doi: 10.1007/s11684-019-0683-y

Abstract: In recent years, the development of tumor immunotherapy especially chimeric antigen receptor T (CAR-TEpidermal growth factor receptor variant III (EGFRvIII) is a tumor-specific mutation expressed in various

Keywords： chimeric antigen receptor T cells     epidermal growth factor receptor     lung cancer     immunotherapy     tumor immunolog    

HTML PDF Collect

Blockage of receptor-interacting protein 2 expression by small interfering RNA in murine macrophages

LIU Hongchun, CAO Zhongwei, JIN Jianjun, WANG Jiyao

Frontiers of Medicine 2008, Volume 2, Issue 2,   Pages 166-170 doi: 10.1007/s11684-008-0030-1

Abstract: This study aims to demonstrate that blocking the receptor-interacting protein2 (Rip2) expression can
HTML PDF Collect

Soluble triggering receptor expressed on myeloid cell-1 (sTREM-1): a potential biomarker for the diagnosis

Changlin Cao, Jingxian Gu, Jingyao Zhang

Frontiers of Medicine 2017, Volume 11, Issue 2,   Pages 169-177 doi: 10.1007/s11684-017-0505-z

Abstract: An example of these biomarkers is triggering receptor expressed on myeloid cell-1 (TREM-1), which isa cell surface receptor expressed on monocytes/macrophages and neutrophils.

Keywords： soluble triggering receptor expressed on myeloid cells-1     infectious diseases     diagnosis and prognosis    

HTML PDF Collect

Gene and protein expression of proteinase-activated receptor-1, 2 in a murine model of acute graft host

Quan LI MD , Weiming LI MD , Ping ZOU MD , Jian ZHANG BM ,

Frontiers of Medicine 2009, Volume 3, Issue 3,   Pages 309-315 doi: 10.1007/s11684-009-0043-4

Abstract: Proteinase-activated receptors (PARs) are a novel subclass of seven transmembrane-spanning, G protein-coupled receptors. PAR-1 and PAR-2 are widely expressed in a variety of cells and are found to be involved in many physiological and pathological processes including inflammation and immune response. However, little is known about the function of PAR-1, 2 in acute graft host disease (GVHD). In the present study, we first detected the expression of PAR-1, 2 protein and mRNA in a murine model of acute GVHD using the methods of immunohistochemistry, Western blot and quantitative real-time polymerase chain reaction (PCR). Syngeneic hematopoietic stem cell transplantation (HSCT) mice served as controls. The relative gene expression level of PAR-1 was significantly increased in the skin, liver, small intestine of allogeneic HSCT mice (in skin: 0.039±0.013 0.008±0.002 of controls, =0.009; in liver: 0.165±0.006 0.017±0.006 of controls, =0.004; in small intestine: 0.215±0.009 0.016±0.002 of controls, =0.003), but not in the stomach, lung and kidney of allogeneic HSCT mice (>0.05). PAR-2 mRNA expression in the liver and small intestine of allogeneic HSCT mice (in liver: 0.010±0.002 0.003±0.001 of controls, =0.008; in small intestine: 0.006±0.001 0.003±0.001 of controls, =0.024) was increased significantly, but PAR-2 mRNA expression in the other organs (>0.05) was not found to be significantly elevated. PAR-1, 2 protein expression was in accordance with the mRNA expression, as shown by Western blot. Using immunohistochemistry the present study demonstrated that there was strong PAR-1, 2 immunoreactivity in the epithelial cell and vascular endothelial cell of target organs of acute GVHD. Our findings of markedly increased expression of PAR-1, 2 in target organs of acute GVHD suggest that PAR-1 and PAR-2 may play an important role in the pathogenesis of acute GVHD.

Keywords： graft vs host disease     proteinase-activated receptor     murine model     hematopoietic stem cell transplantation    

HTML PDF Collect

A giant step forward: chimeric antigen receptor T-cell therapy for lymphoma

Houli Zhao, Yiyun Wang, Elaine Tan Su Yin, Kui Zhao, Yongxian Hu, He Huang

Frontiers of Medicine 2020, Volume 14, Issue 6,   Pages 711-725 doi: 10.1007/s11684-020-0808-3

Abstract: Chimeric antigen receptor T (CAR-T) cells were introduced as a treatment for these patients.

Keywords： chimeric antigen receptor T (CAR-T) cell     lymphoma     cytokine release syndrome (CRS)     immune effector cell-associated    

HTML PDF Collect

Title Author Date Type Operation

FGF23 associated bone diseases

Eryuan Liao

Journal Article

The FGF metabolic axis

Xiaokun Li

Journal Article

FGF13 suppresses acute myeloid leukemia by regulating bone marrow niches

Journal Article

Influence of retinoic acid on TBX1 expression in myocardial cells induced by Shh and Fgf8

Miao LIU, Xiaoyan WU, Jiawei XU, Runming JIN

Journal Article

Nicotinic acetylcholine receptor α7 subunit: a novel therapeutic target for cardiovascular diseases

Chong Liu, Dingfeng Su

Journal Article

Resistance to receptor tyrosine kinase inhibition in cancer: molecular mechanisms and therapeutic strategies

Peter B. Alexander,Xiao-Fan Wang

Journal Article

Fibroblast growth factor 21: a novel metabolic regulator from pharmacology to physiology

Huating Li, Jing Zhang, Weiping Jia

Journal Article

Overcoming resistance to endocrine therapy in hormone receptor-positive human epidermal growth factorreceptor 2-negative (HR

Wenjie Zhu, Binghe Xu

Journal Article

microenvironment contributes to tumor progression in diffuse large B-cell lymphoma upon anti-CD19 chimeric antigen receptor

Journal Article

Chimeric antigen receptor T cell therapies for acute myeloid leukemia

Bin Gu, Jianhong Chu, Depei Wu

Journal Article

Chimeric antigen receptor T cell targeting EGFRvIII for metastatic lung cancer therapy

Zhao Zhang, Jun Jiang, Xiaodong Wu, Mengyao Zhang, Dan Luo, Renyu Zhang, Shiyou Li, Youwen He, Huijie Bian, Zhinan Chen

Journal Article

Blockage of receptor-interacting protein 2 expression by small interfering RNA in murine macrophages

LIU Hongchun, CAO Zhongwei, JIN Jianjun, WANG Jiyao

Journal Article

Soluble triggering receptor expressed on myeloid cell-1 (sTREM-1): a potential biomarker for the diagnosis

Changlin Cao, Jingxian Gu, Jingyao Zhang

Journal Article

Gene and protein expression of proteinase-activated receptor-1, 2 in a murine model of acute graft host

Quan LI MD , Weiming LI MD , Ping ZOU MD , Jian ZHANG BM ,

Journal Article

A giant step forward: chimeric antigen receptor T-cell therapy for lymphoma

Houli Zhao, Yiyun Wang, Elaine Tan Su Yin, Kui Zhao, Yongxian Hu, He Huang

Journal Article